NCT03422029Unknown2 期
Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
Peking University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2018年1月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Overall response rate (ORR)
研究概览
简要总结
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Dotatate in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of GEP-NEN
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •sign written informed consent form
- •age ≥ 18 years
- •pathologically confirmed well-differentiated neuroendocrine tumors;
- •unresectable metastatic tumors confirmed by radiological imaging;
- •Somatostatin receptor positive (SSTR+) disease;
- •Radiological disease progression within 12 months, defined as progressive disease per RECIST 1.
- •No more than 2 prior antitumor drugs, including somatostatin analogs, targeted drugs and chemotherapy, with the last dose over 4 weeks;
- •At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine CT scan >=20mm, spiral CT scan >=10mm, no prior radiation to measurable lesions);
- •Screening laboratory values must meet the following criteria (within past 7 days): hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum creatinine ≤1╳ULN;
- •Predicted survival >=3 months;
- •Negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women;
- •Sexually active males or females willing to practice contraception during the study until 30 days after end of study.
排除标准
- •Hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or everolimus or any other Rapamycin derivative;
- •Prior antitumor therapy (including corticosteroids and immunotherapy) or participation in other clinical trials within past 4 weeks, or have not recovered from toxicities since the last treatment;
- •Received surgery within past 4 weeks, or have not recovered from surgery;
- •Concurrent severe infection；
- •Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including severe liver disease (active hepatitis, cirrhosis), uncontrolled diabetes or hypertension, or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
- •Prior long term steroid therapy (excluding short term steroid treatment which is completed prior to > 2 weeks of study enrollment)；
- •Meningeal carcinomatosis;
- •Patients with central nervous system(CNS) disorder or peripheral nervous system disorder or psychiatric disease；
- •Known history of uncontrolled or symptomatic angina, uncontrolled arrhythmias and hypertension, or congestive heart failure, or cardiac infarction within 6 months prior to study enrollment, or cardiac insufficiency；
- •Pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study;
- •History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible；
- •Person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；
- •Underlying medical condition that, in the Investigator's opinion, would increase the risks of study drug administration or obscure the interpretation of toxicity determination or adverse events.
研究组 & 干预措施
177Lu-Dotatate PRRT
Experimental
177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
干预措施: 177Lu-Dotatate PRRT (Drug)
结局指标
主要结局
Overall response rate (ORR)
时间窗: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
CT/MRI will be performed every 8 weeks for efficacy evaluation by RECIST 1.1 and CHOI
Incidence of Treatment-related Adverse Events（Safety and Tolerability）
时间窗: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
次要结局
- Progression-free survival(baseline, every 8 weeks up to 1 year after last patient first treatment)
研究者
Shen Lin
MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital
Peking University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine TumorsNeuroendocrine TumorsGastro Entero Pancreatic Neuroendocrine TumorsNCT02736500Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori39
撤回
2 期
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsNeuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid TumorGastroenteropancreatic Neuroendocrine TumorVipomaGastrinomaInsulinomaNCT04915144British Columbia Cancer Agency
进行中（未招募）
3 期
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsNeuroendocrine TumorsNCT03049189ITM Solucin GmbH324
已完成
1 期
Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 AntibodyProstate CancerNCT00538668Weill Medical College of Cornell University55
进行中（未招募）
2 期
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCGenital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsProstatic DiseaseProstate CancerProstatic NeoplasmsNCT05150236Australian and New Zealand Urogenital and Prostate Cancer Trials Group93